Content Conference Coverage Conferences CROI2017
CROI 2017: Dolutegravir Monotherapy Fails to Maintain Viral Suppression
- Details
- Category: HIV Treatment
- Created on Wednesday, 08 March 2017 00:00
Dolutegravir used alone without other antiretrovirals was unable to keep viral load suppressed in some people who switched from a standard 3-drug combination regimen, according to research presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. But evidence continues to show that dolutegravir plus a single other drug can work well as maintenance therapy.
CROI 2017: Integrase Inhibitors May Increase Risk of IRIS in Late Presenters for HIV Treatment
- Details
- Category: HIV Treatment
- Created on Wednesday, 08 March 2017 00:00
HIV integrase inhibitors such as dolutegravir and raltegravir may increase the risk of immune reconstitution inflammatory syndrome or IRIS, according to studies from the Netherlands and France presented last month at the Conference on Retroviruses and Opportunistic Infections in Seattle.
CROI 2017: Treatment-as-Prevention Study Sees Substantial Drug Resistance, but No Impact on HIV Therapy
- Details
- Category: HIV Treatment
- Created on Tuesday, 28 February 2017 00:00
A study of the prevalence of transmitted drug resistance among participants in the ANRS 12249 trial of treatment as prevention, has found that a substantial minority of participants had HIV with drug resistance mutations. However, there was no evidence that pre-existing drug resistance had any impact on the success of treatment, according to a report at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
CROI 2017: Time with Transmissible HIV Viral Load Has Fallen By Three-Quarters Since 2000
- Details
- Category: HIV Treatment
- Created on Tuesday, 28 February 2017 00:00
A study by the Centers for Disease Control and Prevention (CDC) presented at the recent Conference on Retroviruses and Opportunistic Infections in Seattle found that the proportion of time people with HIV in the U.S. spend in care but not virally suppressed has fallen from 40% to 10% in the last 15 years. The study also found that young people, black people, and people with public rather than private health coverage spent less time with viral load below 1500 copies/mL, the World Health Organization (WHO) threshold for HIV transmission.
CROI 2017: New NNRTI Doravirine Shows Good Efficacy in Phase 3 Study
- Details
- Category: HIV Treatment
- Created on Monday, 20 February 2017 00:00
Doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) from Merck, reduced HIV viral load as well as boosted darunavir in a Phase 3 clinical trial of people starting antiretroviral therapy (ART) for the first time, but it had a better lipid profile, according to a late-breaking presentation at the Conference on Retroviruses and Opportunistic Infections last week in Seattle.
More Articles...
- CROI 2017: Changes In Viral Suppression Over Time Reveal Disparities in HIV Care
- CROI 2017: Dual Antiretroviral Regimen Maintains Durable HIV Suppression after Switch
- CROI 2017: Several New Candidates in HIV Drug Pipeline Discussed at Conference
- CROI 2017: New HIV Capsid Inhibitors Show High Potency and Prolonged Activity in Early Studies
- CROI 2017: Monoclonal Antibodies Show Promise for HIV+ People with Few Treatment Options
- CROI 2017: Integrase Inhibitor Bictegravir Matches Dolutegravir for First-Line HIV Treatment
- CROI 2017: How Does Vedolizumab Antibody Therapy Lead to Sustained Viral Remission?
- CROI 2017: Timothy Brown, the Berlin Patient, Celebrates a Decade Cured of HIV
- CROI 2017: Bone Marrow Transplant Patient Off ART for 288 Days Without HIV Rebound
- CROI 2017: Spanish HIV Vaccine Induces Control Off ART in Nearly 40% of Recipients
- CROI 2017: Science, Community, and Political Will Can End HIV Epidemic, Says New York Commissioner
- CROI 2017: Bacterial Vaginosis Does Not Affect Efficacy of Oral PrEP in Women
- CROI 2017: STI Rates Among PrEP Users Are High, But Evidence that PrEP Increases Them Is Inconclusive
- CROI 2017: Unique Case of PrEP Failure Without Drug Resistance Reported in Amsterdam
- CROI 2017: STI Prophylaxis in PrEP Users Reduces Syphilis and Chlamydia, but Not Gonorrhea
- CROI 2017: Point-of-Care Testing Improves Infant HIV Diagnosis Rate, Treatment, and Retention
- CROI 2017: How Should HIV Self-Testing Be Provided?
- CROI 2017: HIV's Milder Cousin May Be Less Mild than Previously Thought
- CROI 2017: Stopping Smoking Cuts Risk of Some Cancers Quickly in People with HIV
- CROI 2017: Treatment or Watchful Waiting for Cervical Abnormalities in Women with HIV?
- CROI 2017: Long-Term Darunavir/Ritonavir Modestly Increases Risk of Cardiovascular Disease
- CROI 2017: Bone Density Improves in People Who Switch from Tenofovir DF to Tenofovir Alafenamide
- CROI 2017: Better Depression Care Could Improve Outcomes for HIV Treatment Programs
- CROI 2017: Studies Look at Brain and Cognitive Changes in People with HIV As They Age
- CROI 2017: 1 in 5 HIV+ Men in U.K. Who Say They Are Heterosexual Caught HIV from Another Man
- CROI 2017: Simple Risk Score Can Identify Gay Men Who May Have Acute HIV Infection
- CROI 2017: Finding Men with HIV -- and Keeping Them in Treatment
- CROI 2017: A Combination of Factors Has Reduced HIV Infections in Hard-Hit Part of Africa
- CROI 2017: Efavirenz/ Tenofovir/Emtricitabine Less Likely to Cause Adverse Birth Outcomes
- CROI 2017: Infants Treated Within Days of Birth Can Clear HIV Reservoir Rapidly
- CROI 2017: Will There Be a New Wave of HIV Among People Who Inject Drugs in the U.S.?
- CROI 2017: Accelerated Linkage to HIV Care Improves Retention by a Third
- CROI 2017: Test and Treat Study Shows Second Phase Is Finding More People with HIV
- CROI 2017: Peer Navigators Improve Linkage to HIV Care and Retention in South African Study
- CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals
- CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?
- CROI 2017: Hepatitis C Treatment Can Be Provided Successfully at Syringe Exchange Sites
- CROI 2017: Higher than Expected HCV Prevalence Among HIV- Gay Men in Amsterdam PrEP Program
- CROI 2017: DAA Therapy Cures HIV/HCV Coinfected People with Decompensated Cirrhosis or Transplants
- CROI 2017: Prednisone Reduces Risk of Developing TB-IRIS after Starting Antiretroviral Treatment
- CROI 2017: Isoniazid Preventive Therapy for TB Reduces Risk of Death for People Living with HIV
- CROI 2017: Triple Tuberculosis Regimen Beats XDR-TB in First Trial
Web Design and Development by